Hepatitis B virus clearance rate estimates

macol Toxicol 2005;45:51-88. 3. Agundez JAG, Ladero JM. Glutathione S-transferase GSTT1 and GSTM1 allozymes: beyond null alleles. Pharmacogenomics 2008;9:359-363. 4. Sun F, Chen Y, Xiang Y, Zhan S. Drug metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008;12:994-1002. 5. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, Garcı́aRuiz E, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129:512-552. This letter was written on behalf of the Spanish Group for the Study of DrugInduced Liver Disease (Grupo de Estudio para las Hepatopatias Asociadas a Medicamentos). M. Isabel Lucena, Raúl J. Andrade, and Eugenia Ulzurrun are associated with the Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas. Carmen Martı́nez, Elena Garcı́a-Martı́n, and José A. G. Agúndez are associated with the Red de Investigación de Reacciones Adversas a Alergenos y Fármacos. Copyright © 2009 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hep.22910 Potential conflict of interest: Nothing to report.

[1]  A. Lohse,et al.  Virion half‐life in chronic hepatitis B infection is strongly correlated with levels of viremia , 2008, Hepatology.

[2]  Sebastian Bonhoeffer,et al.  Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis , 1999, The Lancet.

[3]  A S Perelson,et al.  Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. , 1998, Science.

[4]  A. Hatzakis,et al.  A viral kinetic study using pegylated interferon alfa‐2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative , 2005, Hepatology.

[5]  J. Koskinas,et al.  Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients , 2006, Hepatology.

[6]  Robert Edwards,et al.  Glutathione Transferases , 2010, The arabidopsis book.

[7]  S. Zeuzem,et al.  Viral dynamics in chronic hepatitis B patients during lamivudine therapy. , 2002, Liver.

[8]  Alan S. Perelson,et al.  Rapid Clearance of Simian Immunodeficiency Virus Particles from Plasma of Rhesus Macaques , 1999, Journal of Virology.

[9]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[10]  R. Gieschke,et al.  A Multiphase Model of the Dynamics of HBV Infection in Hbeag-Negative Patients during Pegylated Interferon-α2A, Lamivudine and Combination Therapy , 2005, Antiviral therapy.

[11]  R. Purcell,et al.  The half‐life of hepatitis B virions , 2006, Hepatology.

[12]  Alan S. Perelson,et al.  Analysis of hepatitis B viral load decline under potent therapy: Complex decay profiles observed , 2001, Hepatology.

[13]  Nancy Haigwood,et al.  Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma , 1999, Nature Medicine.

[14]  P. Schirmacher,et al.  Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B , 2006, Hepatology.

[15]  Eva Herrmann,et al.  Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. , 2005, Journal of hepatology.